CYCN
NASDAQCyclerion Therapeutics Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$3.24+0.03 (+0.93%)
06:45 PM07:45 PM
News · 26 weeks13-67%
2025-12-212026-06-14
Mix890d
- SEC Filings6(75%)
- Earnings1(13%)
- Other1(13%)
Latest news
25 items- SECAmendment: SEC Form S-4/A filed by Cyclerion Therapeutics Inc.S-4/A - Cyclerion Therapeutics, Inc. (0001755237) (Filer)
- SECSEC Form 10-Q filed by Cyclerion Therapeutics Inc.10-Q - Cyclerion Therapeutics, Inc. (0001755237) (Filer)
- SECSEC Form SCHEDULE 13G filed by Cyclerion Therapeutics Inc.SCHEDULE 13G - Cyclerion Therapeutics, Inc. (0001755237) (Subject)
- SECAmendment: SEC Form 10-K/A filed by Cyclerion Therapeutics Inc.10-K/A - Cyclerion Therapeutics, Inc. (0001755237) (Filer)
- SECSEC Form S-4 filed by Cyclerion Therapeutics Inc.S-4 - Cyclerion Therapeutics, Inc. (0001755237) (Filer)
- SECSEC Form 425 filed by Cyclerion Therapeutics Inc.425 - Cyclerion Therapeutics, Inc. (0001755237) (Subject)
- SECCyclerion Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure8-K - Cyclerion Therapeutics, Inc. (0001755237) (Filer)
- PRCyclerion Therapeutics and Korsana Biosciences Announce Merger AgreementCombined company to operate as Korsana Biosciences and to advance Korsana's potential best-in-class therapeutics to treat neurodegenerative diseases Korsana's lead program KRSA-028 is a next-generation shuttled monoclonal antibody targeting amyloid beta for the treatment of Alzheimer's disease Concurrent private financing of approximately $380 million expected to fund Korsana's operations into 2029, including multiple clinical trial data readouts expected in 2027 Conference call scheduled for April 1, 2026, at 8:00 am ET Cyclerion Therapeutics, Inc. ("Cyclerion") (NASDAQ:CYCN) and Korsana Biosciences, Inc. ("Korsana"), a privately-held biotechnology company discovering and developin
- SECCyclerion Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Cyclerion Therapeutics, Inc. (0001755237) (Filer)
- PRCyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board–Received Positive Pre-Investigational New Drug ("IND") Written Feedback from the U.S. Food and Drug Administration ("FDA")– –Clinical Advisory Board ("CAB") Includes Key Leaders across Neuropsychiatry, Anesthesiology, and Clinical Development– –Remain On Track to Initiate CYC-126's Phase 2 Proof-of-Concept ("POC") Study in Treatment Resistant Depression ("TRD") in the Second Half of 2026– CAMBRIDGE, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) ("Cyclerion" or "Company"), a biopharmaceutical company pioneering neuropsychiatric therapies, today announced it has received positive written regulatory feedback and responses from the FDA on CYC-126
- PRMorning Market Brief: Breakthrough Biology Meets Scalable Platforms as Innovators Surge into FocusDENVER, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Markets are opening with a clear appetite for substance over speculation, as investors gravitate toward companies delivering late-stage clinical wins, scalable science, and data-driven precision platforms. Alumis (NASDAQ:ALMS): Phase 3 Data Redefines the Oral Psoriasis Landscape Alumis is firmly in focus after announcing positive topline results from two Phase 3 trials (ONWARD1 and ONWARD2) evaluating envudeucitinib, its next-generation oral TYK2 inhibitor, in moderate-to-severe plaque psoriasis. Both trials met all primary and secondary endpoints with high statistical significance, with efficacy that stands out among oral therapies. By Week 24,
- SECCyclerion Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Cyclerion Therapeutics, Inc. (0001755237) (Filer)
- PRCyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression– Cyclerion Strengthens Development of Closed-Loop Anesthetic Platform through Strategic Collaboration Agreement with Medsteer – – Comprehensive Business Update and Path to Initiating Phase 2 Proof-of-Concept ("POC") Study in the Second Half of 2026 – – Webcast Being Held on January 6, 2026 at 8:00 a.m. ET, Featuring Key Opinion Leader, Dr. Husseini Manji – CAMBRIDGE, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), a biopharmaceutical company pioneering neuropsychiatric therapies, today announced an application-specific, exclusive collaboration with Medsteer, a leader in anesthetic delivery systems driven by real-time patient feedback. The new collab
- SECSEC Form 8-K filed by Cyclerion Therapeutics Inc.8-K - Cyclerion Therapeutics, Inc. (0001755237) (Filer)
- SECSEC Form 10-Q filed by Cyclerion Therapeutics Inc.10-Q - Cyclerion Therapeutics, Inc. (0001755237) (Filer)
- SECAmendment: SEC Form 10-K/A filed by Cyclerion Therapeutics Inc.10-K/A - Cyclerion Therapeutics, Inc. (0001755237) (Filer)
- SECSEC Form SCHEDULE 13G filed by Cyclerion Therapeutics Inc.SCHEDULE 13G - Cyclerion Therapeutics, Inc. (0001755237) (Subject)
- SECCyclerion Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Cyclerion Therapeutics, Inc. (0001755237) (Filer)
- PRCyclerion Announces Transformational Relaunch as a Neuropsychiatric Company– Cyclerion Relaunches, Advancing a Phase 2–Ready Program for Millions Living with Treatment-Resistant Depression Through MIT License Agreement – – Webcast to be held September 24, 2025 at 10:30 a.m. ET – CAMBRIDGE, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. today announced that it has entered into a licensing agreement with the Massachusetts Institute of Technology ("MIT"), securing the intellectual property that will serve as the cornerstone of its strategic relaunch. This agreement marks a pivotal milestone in Cyclerion's transformation into a new, innovation-driven company focused on delivering potential novel, improved or first--in-class therapies for neu
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Cyclerion Therapeutics Inc.SCHEDULE 13G/A - Cyclerion Therapeutics, Inc. (0001755237) (Subject)
- INSIDERSEC Form 4 filed by Chief Financial Officer Chicko Rhonda M.4 - Cyclerion Therapeutics, Inc. (0001755237) (Issuer)
- SECSEC Form 10-Q filed by Cyclerion Therapeutics Inc.10-Q - Cyclerion Therapeutics, Inc. (0001755237) (Filer)
- SECSEC Form 8-K filed by Cyclerion Therapeutics Inc.8-K - Cyclerion Therapeutics, Inc. (0001755237) (Filer)
- SECSEC Form EFFECT filed by Cyclerion Therapeutics Inc.EFFECT - Cyclerion Therapeutics, Inc. (0001755237) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Cyclerion Therapeutics Inc.SCHEDULE 13G/A - Cyclerion Therapeutics, Inc. (0001755237) (Subject)
CYCN FAQ
6 questionsWhat does Cyclerion Therapeutics Inc. do?
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its product candidates include CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase II trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) and Alzheimer's disease with vascular pathology (ADv); Olinciguat, an orally administered vascular soluble guanylate cyclase stimulator that is in Phase II studies for...Where does CYCN stock trade?
Cyclerion Therapeutics Inc. (CYCN) is listed on NASDAQ.What sector and industry is CYCN in?
Cyclerion Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about CYCN?
Cyclerion Therapeutics Inc. has had 2 recent analyst actions on file. The most recent action was from Truist Securities: Buy with a $1400.00 price target on 2021-10-20. Recent price targets range from $700.00 to $1400.00.What companies are similar to CYCN?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare CYCN side-by-side with any of them on Quantisnow.How can I track CYCN on Quantisnow?
Quantisnow aggregates Cyclerion Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CYCN to receive live email and push alerts on every new disclosure.